Enlivex Therapeutics Ltd.
ENLV | TA
Overview
Corporate Details
- ISIN(s):
- IL0011319527
- LEI:
- Country:
- Israel
- Address:
- Weizmann Science Park, 14 Einstein St., 7403618 Ness Ziona
- Website:
- https://enlivex.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Enlivex develops immunotherapy solutions for inflammatory diseases and critical conditions.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Enlivex Therapeutics Ltd..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-08-14 17:54 |
Foreign Filer Report
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Ost…
|
English | 173.8 KB | |
| 2025-08-14 17:54 |
Foreign Filer Report
Enlivex to Present 3-Month Topline Data from Phase IIa Moderate/Severe Knee Ost…
|
English | 36.3 KB | |
| 2025-07-28 17:42 |
Foreign Filer Report
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II T…
|
English | 149.8 KB | |
| 2025-07-28 17:42 |
Foreign Filer Report
Enlivex Reaffirms August 18, 2025 As Target Date For Announcement of Phase II T…
|
English | 36.3 KB | |
| 2025-05-31 01:44 |
Foreign Filer Report
Financial statements as of a March 31, 2025
|
English | 271.6 KB | |
| 2025-05-31 01:44 |
Foreign Filer Report
Financial statements as of a March 31, 2025
|
English | 36.5 KB | |
| 2025-05-14 01:32 |
Prospectus
Renewal of ATM plan
|
English | 545.8 KB | |
| 2025-05-14 01:32 |
Foreign Filer Report
Renewal of ATM plan
|
English | 36.3 KB | |
| 2025-05-03 02:24 |
Registration Form
FORM F-3-prospectus in one or more offerings
|
English | 617.9 KB | |
| 2025-05-03 02:24 |
Foreign Filer Report
FORM F-3-prospectus in one or more offerings
|
English | 36.3 KB | |
| 2025-05-01 02:02 |
Foreign Filer Report
20F For the fiscal year ended December 31, 2024
|
English | 1.7 MB | |
| 2025-05-01 02:02 |
Foreign Filer Report
20F For the fiscal year ended December 31, 2024
|
English | 36.5 KB | |
| 2025-04-23 17:45 |
Foreign Filer Report
To Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
|
English | 175.9 KB | |
| 2025-04-23 17:45 |
Foreign Filer Report
To Showcase Allocetra’s Potential in Osteoarthritis at OARSI 2025 World Congress
|
English | 36.2 KB | |
| 2025-04-21 18:05 |
Foreign Filer Report
Completion of Enrollment In The Phase II stage Of Its Phase I/II Trial Evaluati…
|
English | 150.2 KB |
Automate Your Workflow. Get a real-time feed of all Enlivex Therapeutics Ltd. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Enlivex Therapeutics Ltd. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
Novo Nordisk | Denmark | NOVO | |
|
NRGene Technologies Ltd. | Israel | NRGN | |
|
NUFORMIX PLC | United Kingdom | NFX | |
|
Nykode Therapeutics ASA | Norway | NYKD | |
|
Oculis Holding AG | Switzerland | OCS | |
|
ONCODESIGN | France | ALONC | |
|
Oncodesign Precision Medicine S.A | France | ALOPM | |
|
Oncoinvent ASA | Norway | OCIN | |
|
Oncopeptides | Sweden | ONCO | |
|
Onxeo | France | ALONX |